BeyondSpring Pharmaceuticals to Conduct Phase 3 Trial of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BeyondSpring Pharmaceuticals to Conduct Phase 3 Trial of Lead Candidate Plinabulin in NSCLC

NEW YORK, Dec. 3, 2014 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it plans to initiate a Phase 3 pivotal trial of lead product candidate, Plinabulin, in patients with non-small cell lung cancer (NSCLC) in the first quarter of 2015. The planned initiation of the Phase 3 trial follows the presentation of positive data from a Phase 2 clinical trial evaluating Plinabulin at the 50 th American Society of Clinical Oncology (ASCO) Annual Meeting, held on May 30 – June 3, 2014 in Chicago, Illinois.

Plinabulin is an anti-cancer agent with a unique mechanism of action. It has multi-faceted activities that have been shown to exhibit anti-tumor activity through anti-angiogenesis, obliteration of existing tumor vasculature and induction of tumor cell apoptosis via the JNK pathway.

The completed Phase 1b/2, open-label trial (NCT00630110) in patients with advanced (Stage 3b/4) NSCLC compared the efficacy and safety of the combination of Plinabulin and docetaxel to docetaxel alone. Results of the trial were presented in a poster titled "Randomized phase 2 trial of plinabulin (NPI-2358) plus docetaxel in patients with advanced non-small cell lung cancer (NSCLC)," ( Abstract #8054 ) i during a general poster session on "Lung Cancer - Non-Small Cell Metastatic"

Dr. Lan Huang, Ph.D., Chief Executive Officer of BeyondSpring Pharmaceuticals, commented, "The data from our Phase 2 study validated Plinabulin's unique mechanism of action and allowed us to tailor our next trial using a unique biomarker-driven approach to patients who will be most likely to benefit from treatment with Plinabulin, such as those with large lung cancer lesions, and thus more dependent on the abundant tumor vasculature. Our Phase 2 study demonstrated a longer median overall survival for this particular subset of patients – 11.5 months for combination Plinabulin plus docetaxel compared to just 7.8 months for patients receiving docetaxel alone. This is a substantial improvement compared to approved lung cancer drugs which, in pivotal trials, demonstrated overall survival of approximately 8 months. Furthermore, over the last 15 years, few drugs have received FDA approval specifically for second-line NSCLC with EGFR and ALK wild type patients, who typically have much shorter survival time than EGFR and ALK mutant patients. Given this, there is a critical unmet medical need for NSCLC patients without EGFR or ALK mutations. Our data have shown that Plinabulin activities are independent of EGFR, ALK mutations. We believe Plinabulin would be an important addition to the armamentarium for this difficult to treat disease."

In the Phase 2 portion of this study, a total of 172 patients with NSCLC who had progressed after at least one chemotherapy regimen for advanced disease were randomized 1:1 to receive docetaxel alone (75 mg/m 2 ) or docetaxel (75 mg/m 2 ) in combination with either Plinabulin at 30 mg/m 2 (30 Cohort) or 20 mg/m 2 (20 Cohort). A total of 163 patients were treated. The primary endpoint was overall survival (OS), with secondary endpoints including progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety. The study also aimed to identify, on an exploratory basis, a subset of patients that responds better to combination therapy of Plinabulin and docetaxel.

The study demonstrated encouraging efficacy results. In the 30 Cohort, median OS at a 90% confidence interval (CI) was 8.7 months for Plinabulin and docetaxel combination, compared to 7.5 months for docetaxel alone; although ORRs were comparable between treatments, 14.0% for combination and 14.5% for docetaxel alone, the DOR at 90% CI for the combination was superior to docetaxel alone, 12.7 months compared to 1.5 months, respectively, (p=0.049). Furthermore, results from the combination of Plinabulin and docetaxel 30 Cohort appeared better than those from the 20 Cohort.

In addition, post hoc exploratory analysis identified mechanism-targeted patients as those with large lung tumors (greater than 3 cm). In this subpopulation, patients who had one prior chemotherapy for advanced disease experienced apparent survival benefit from Plinabulin and docetaxel combination relative to docetaxel alone. Median OS at 95% CI for this subset was 11.5 months for the combination compared to 7.8 months docetaxel alone. Based on this observation, BeyondSpring plans to initiate a Phase 3 trial enriched for patients who will most likely benefit from the known mechanism of action of Plinabulin, namely, a tumor vasculature targeting agent with apoptotic properties via JNK pathway.

Overall, Plinaublin is well tolerated in combination with docetaxel. The majority of adverse events were mild to moderate. The most frequent adverse events were nausea, fatigue, diarrhea, constipation, and loss of appetite, occurring in less than 50% of patients. Among patients receiving Plinabulin and docetaxel combination, the most frequent severe (Grade 3) or life-threatening (Grade 4) adverse event was transient hypertension in 20% of patients, while Grade 3 or 4 neutropenia was observed in less than 8% of patients – which is much lower than the 29% of patients in the docetaxel alone group. Neutropenia is an abnormally low count of neutrophils, a type of white blood cell important in fighting infection. Severe neutropenia may lead to life-threatening infection and often necessitates reducing the dose of docetaxel. Consistent with less frequent neutropenia, fewer dose reductions of docetaxel (10%) were necessary for patients in the combination group than among patients receiving docetaxel alone (18.2%). Similar observations were made in both the 30 Cohort and the 20 Cohort.

Dr. Gloria Lee, M.D., Ph.D., Chief Medical Officer of BeyondSpring, added, "Based on these data, we are able to utilize our unique mechanism-based approach to tailor the design of the Phase 3 trial to include patients with large tumors. Starting the trial in the first quarter of 2015, we plan to enroll approximately 500 patients at up to 35 sites between China and the U.S.  Following consultation with the U.S. FDA, we expect to enroll approximately 75% of patients at the China sites, with the remaining 25% enrolled through sites in the U.S. Leveraging our unique, cross-border development model, we expect to substantially enhance the efficiency of resource utilization with respect to both the enrollment time and cost for this pivotal study."

Dr. Lee, a veteran in oncology drug development, joined BeyondSpring earlier this year. During her 22-year career, Dr. Lee has held a number of high-level clinical and development positions, including serving as Chief Medical Officer of immuno-oncology company Kite Pharma. Among Dr. Lee's career accomplishments are the Taxotere New Drug Application (NDA), Phase 4 programs at Rhone-Poulenc Rorer (now Sanofi) and initial clinical development of Zytiga at Cougar Biotechnology (acquired by Johnson & Johnson). Dr. Lee received a Ph.D. in molecular biology from Columbia University and an M.D. from the University of Miami. She was an internal medicine resident at Georgetown University Hospital and a Hematology and Oncology fellow at Fox Chase Cancer Center.

About Non-Small Cell Lung Cancer

Lung cancer is the leading cause of cancer deaths in the world. In 2012, there were approximately 1.8 million new cases and 1.6 million estimated deaths worldwide. There are two main types of lung cancer: Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), which is the more common form, accounting for approximately 85 percent of all lung cancers.

About BeyondSpring Pharmaceuticals

BeyondSpring Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring is focused on the advancement and commercialization of Plinabulin, a novel, Phase 3-ready cancer therapeutic initially targeting non-small-cell lung cancer (NSCLC). Led by an expert management team consisting of pharmaceutical industry veterans from the U.S. and China, the Company is well positioned to further advance lead product candidate, Plinabulin. For more information, visit www.beyondspringpharma.com . 

References

i Heist. R.S. et al. "Randomized phase 2 trial of plinabulin (NPI-2358) plus docetaxel in patients with advanced non-small cell lung cancer (NSCLC)." Abstract 8054. ASCO Annual Meeting, 2014. J Clin Oncol 32:5s, 2014 (suppl; abstr 8054).

The Ruth Group Lee Roth (investors) (646) 536-7012 Kirsten Thomas (media) (646) 536-7014

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
Azazie Tests Bridal Demand With Two East Coast Pop-Ups

Updated Category News Views 116

Wedding dresses are a miserable product to buy sight unseen, no matter how pretty the product photos look. That basic fact is why Azazie’s two East Coast pop-ups on November 21 and 22 deserve a closer look. This is not some grand retail rollout, and nobody should pretend a pair of short events rewrites the bridal market. But it is a practical test of where a...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 138

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Workday’s EU Cloud Move Raises the Sovereignty Bar Again

Updated Category News Views 19

Europe’s sovereignty squeeze just got a lot more concrete for Workday. The company is taking its EU Sovereign Cloud beyond the usual data-residency talking points by planning an Ireland-based operating company, European leadership, and governance intended to keep decisions on the service and customer data inside Europe. For a platform sitting underneath payroll, HR...

Continue Reading
Scalefusion’s Platinum Win Sharpens Its Brand Story

Updated Category News Views 14

A Film Is Not a Balance Sheet A slick brand film cannot patch a leaky product, but it can make a complicated platform easier to remember. That is the sensible takeaway from Scalefusion’s Platinum Level win at the 2026 MarCom Awards for “One Platform. One Agent. We are Scalefusion.” The recognition is for creative execution, not commercial performance, and anybody...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Diwali at Heritage Shows the Real Estate Community Test

Updated Category News Views 89

Fireworks do not sell a townhome by themselves, but belonging can sure help close the distance between a brochure and a serious purchase. Heritage at South Brunswick recently held a Diwali celebration sponsored by American Properties at South Brunswick LLC, bringing homeowners, families, and the builder's team into the same room for an evening of food, music, dancing,...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 176

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 15

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading

Top 5 Most Recently Viewed Articles

Broad Arrow to Showcase Exclusive BMW Cars in Italy Auction

Updated Category News Views 225

Broad Arrow Auctions Presents Exclusive BMW Event Broad Arrow Auctions is gearing up for an incredible showcase this May, as it proudly partners with the acclaimed Concorso d’Eleganza Villa d’Este. This prestigious event will feature a special BMW-only sale, spotlighting the rich history and legacy of the famed automobile brand. The auction takes place on May 24th and...

Continue Reading
Business Leadership Showcased in The Enterprise World's Newest Editions

Updated Category News Views 177

In 2024, The Enterprise World made waves by showcasing a lineup of remarkable business leaders. Traders and executives alike were keeping an eye on this publication as it spotlighted key figures in the B2B landscape, delivering insights that could very well influence investment decisions. Spotlight on Business Leadership: Who's Leading the Charge? This edition featured...

Continue Reading
How Elon Musk's Market Predictions Missed the Mark

Updated Category News Views 432

In recent times, the financial landscape saw the S&P 500 index rocket by nearly 50%, showcasing unexpected resilience. Traders had their eyes glued to this upward trend as it contradicted earlier predictions of an imminent market crash echoing the catastrophic events of 1929. Musk’s Dark Predictions: A Market Response? Elon Musk, the outspoken CEO of Tesla and SpaceX,...

Continue Reading
ScottsMiracle-Gro Sets Date for Q2 Financial Results Release

Updated Category News Views 229

Overview of ScottsMiracle-Gro's Upcoming Financial Results ScottsMiracle-Gro Company (NYSE: SMG), a prominent player in the lawn and garden industry, is gearing up to release its financial results for the second quarter. This anticipated announcement will take place on a day when U.S. financial markets are active, providing investors and stakeholders with insights into...

Continue Reading
Exploring the Dynamics of the S&P 500 in 2026

Updated Category News Views 257

Understanding the Market Landscape for 2026 As we gaze into the near future, a mixture of economic indicators and market trends is shaping the outlook for 2026. Analysts suggest that a strong year for the S&P 500 may be on the horizon. Historically, the absence of a recession fosters a fertile environment for stock gains, positioning equities well for investor...

Continue Reading